当前位置: 首页 >> 检索结果
341. Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study.
作者: Adam Al-Hakim.;Roochi Trikha.;Ei Ei Phyu Htut.;Onima Chowdhury.;Calman A MacLennan.;Ashlyn Chee.;Arvind Kaul.;James A Poulter.;Catherine Cargo.;James M S Wason.;Sammiya Ahmed.;Tanya N Basu.;Sukanya Gogoi.;James Galloway.;Stephen Jolles.;Anoop Mistry.;Elspeth M Payne.;Rachel S Tattersall.;Taryn Youngstein.;Helen J Lachmann.;Austin Kulasekararaj.;Sinisa Savic.
来源: Lancet Rheumatol. 2025年7卷7期e472-e484页
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently described autoinflammatory disorder with little therapeutic evidence. We compared treatment outcomes of targeted therapies versus prednisolone alone in the largest UK cohort of patients with VEXAS syndrome to date.
342. Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.
作者: Jiachen Li.;Weiyi Xia.;Huijuan Ji.;Xiaoxin Gong.;Qi Dong.;Yanan Wu.;Longjun Wang.;Meixia Peng.;Jingxuan Liu.;Ke Ma.;Qi Yu.;Xinglei Cui.;Yuanyuan Luo.;Wenhua Zhu.;Shumin Zhang.;Shi Chen.;Yuhui Li.;Zhanguo Li.;Tian Liu.
来源: Rheumatology (Oxford). 2025年64卷10期5262-5268页
This study aimed to assess the efficacy and safety of baricitinib in Takayasu arteritis (TAK) refractory to TNF-α inhibitors.
343. Bifidobacterium ameliorates lupus nephritis and modulates aberrant differentiation of lymphocyte subsets.
作者: Lihua Wu.;Zhirong Guan.;Xiaoyu Zhang.;Yanan Liu.;Shuhong Chi.;Xiangguo Duan.;Chunxia Su.
来源: Rheumatology (Oxford). 2025年64卷10期5518-5528页
The gut microbiota is crucial in the progression of lupus nephritis (LN), and probiotics have emerged as a potential therapeutic approach. This study investigates the role of Bifidobacterium in LN pathogenesis and its effects on immune cell populations.
344. Pregnancy outcomes after maternal and paternal anti-IL-1 treatment exposure in cryopyrin-associated periodic syndromes (CAPS).
作者: Özlem Satirer.;Jörg Henes.;Melanie Henes.;Susanne M Benseler.;Jasmin B Kuemmerle-Deschner.
来源: Rheumatology (Oxford). 2025年64卷10期5481-5486页
To determine the effect of paternal and maternal anti-IL-1 treatment exposures on pregnancies and neonatal outcomes in CAPS.
345. Performance of the new PREVENT score for indicating subclinical atherosclerosis in rheumatoid arthritis.
Patients with rheumatoid arthritis (RA) are at increased risk of atherosclerotic cardiovascular disease (ASCVD), yet traditional 10-year CVD risk calculators - such as the 2013 Pooled Cohort Equations (PCE) - underperform in RA. Our objective was to determine the performance of the PCE vs the updated PREVENT algorithm in indicating presence of subclinical coronary and carotid atherosclerosis in RA.
346. Myositis-specific autoantibody subtypes are associated with response to Janus kinase inhibitors in patients with juvenile dermatomyositis.
作者: Brigitte Bader-Meunier.;Thomas R J Moreau.;Florence Aeschlimann.;François-Jérome Authier.;Jean Luc Charuel.;Fabienne Jouen.;Olivier Boyer.;Christine Bodemer.;Anne Welfringer-Morin.;Vincent Bondet.;Benjamin Fournier.;Pierre Quartier.;Marie-Louise Frémond.;Anne-Perrine Foray.;Carlos Sanchez.;Darragh Duffy.;Cyril Gitiaux.;Mathieu P Rodero.
来源: Rheumatology (Oxford). 2025年64卷10期5487-5492页
To evaluate the efficacy and safety of Janus kinase inhibitors (JAKi) in a monocentric series of patients with JDM and to identify factors associated with the achievement of clinically inactive disease (CID).
347. Rheumatic? A diagnostic decision support tool for individuals suspecting rheumatic diseases: Mixed-methods usability and acceptability study.
作者: Stefan Jakobi.;Katharina Boy.;Magali Wagner.;Susann May.;Alp Temiz.;Anna-Maria Liphardt.;Elizabeth Araujo.;Loreto Carmona.;Rachel Knevel.;Georg Schett.;Johannes Knitza.;Felix Muehlensiepen.;Harriet Morf.
来源: BMC Rheumatol. 2025年9卷1期59页
The early diagnosis of inflammatory rheumatic diseases (IRDs) is of paramount importance in order to prevent irreversible damage to joints and to optimize treatment outcomes. Nevertheless, conventional care pathways frequently entail diagnostic delays spanning several months. Symptom checkers (SCs) have the potential to provide a solution by offering validated symptom assessments, improving triage systems and expediting diagnostic evaluations. The objective of this mixed-methods study is to assess the usability and acceptability of the SC Rheumatic? among individuals with suspected rheumatic diseases.
348. A six-month weight loss intervention is associated with significant changes in serum biomarkers related to inflammation, bone and cartilage metabolism in obese patients with psoriatic arthritis and matched controls.
作者: Linda Torres.;Charlotte A Jonsson.;Björn Eliasson.;Helena Forsblad-d'Elia.;Anton J Landgren.;Annelie Bilberg.;Inger Gjertsson.;Ingrid Larsson.;Eva Klingberg.
来源: BMC Rheumatol. 2025年9卷1期58页
Obesity is highly overrepresented in patients with psoriatic arthritis (PsA) and associated with increased disease activity and inferior treatment outcome. We have previously reported in 41 patients with PsA and body mass index (BMI) ≥ 33 kg/m2 that weight loss treatment with Very Low Energy Diet (VLED) resulted in a median weight loss of 18,6% and concomitantly a significant improvement in C-reactive protein (CRP) and disease activity at six months (M6). This sub-study analyzes the effects on serum biomarkers associated with inflammation, bone and cartilage metabolism in the same PsA patients and matched controls.
349. Rheumatologic manifestations in children with underlying inborn errors of immunity.
作者: Zohreh Saeidi.;Sina Fadai.;Mehrnaz Mesdaghi.;Azadeh Zeinab Mirzaee.;Samin Sharafian.;Khosro Rahmani.;Narges Eslami.;Vadood Javadi Parvaneh.;Mahsa Talebi.;Zahra Chavoshzadeh.;Reza Shiari.
来源: BMC Rheumatol. 2025年9卷1期57页
In recent years, many studies have been conducted on the possible link between rheumatologic diseases and inborn errors of immunity. Rheumatologic diseases may occur as manifestations of an underlying immunodeficiency disorder, and may appear before the more-common infectious manifestations more typically seen in immunodeficiency disorders. In this study, we have attempted to study such symptoms and uncover their relationship with inborn errors of immunity.
350. Does body composition matter in patients with systemic sclerosis?
作者: Chiara Giraudo.;Giulia Fichera.;Marco Binda.;Beatrice Moccaldi.;Elisabetta Cocconcelli.;Anna Cuberli.;Anna Michielin.;Andrea Doria.;Roberto Stramare.;Elisabetta Balestro.;Elisabetta Zanatta.
来源: Rheumatology (Oxford). 2025年64卷10期5493-5497页
Body composition plays a significant role in various rheumatic and autoinflammatory diseases. The aim of our study was to assess the impact of muscle mass and subcutaneous adipose tissue quality and quantity in patients with SSc.
351. Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study.
作者: Marina Barguil Macêdo.;Mohamed Javad Wahadat.;Albin Björk.;Sylvia Kamphuis.;Marjan A Versnel.;Christian Lood.
来源: Rheumatology (Oxford). 2025年64卷9期5096-5100页
Mitochondria are prominent antigenic sources, capable of triggering IFN-induced inflammatory pathways in SLE. Recent studies suggest presence of AMA in LN patients with adult-onset SLE. Whether AMA reflect disease activity in childhood-onset SLE (cSLE) remains unexplored. Here, we present inaugural data on the potential utility of AMA as a biomarker in cSLE.
352. Characterization of fibroblast-like synoviocytes from the synovial fluid of patients affected by juvenile idiopathic arthritis.
作者: Simone Pelassa.;Federica Raggi.;Ignazia Prigione.;Francesca Ridella.;Angelo Ravelli.;Marco Gattorno.;Alessandro Consolaro.;Maria Carla Bosco.
来源: Rheumatology (Oxford). 2025年64卷9期5162-5171页
The objectives of this study were to characterize some phenotypic and functional aspects of fibroblast-like synoviocytes isolated from the Synovial Fluid (SF-FLSs) of patients affected by Juvenile Idiopathic Arthritis (JIA) with active disease and to compare SF-FLS characteristics with those reported in the literature for FLSs of the SM (Synovial Membrane) in adult rheumatic patients.
353. Association of matrix metalloproteinase 7 and the alpha-chain of fibrinogen at baseline with response to methotrexate at 3 months in patients with early rheumatoid arthritis.
作者: Karen Hambardzumyan.;Carl Hamsten.;Lucía Lourido.;Saedis Saevarsdottir.;Peter Nilsson.;Ronald F van Vollenhoven.;Per-Johan Jakobsson.;Helena Idborg.
来源: BMC Rheumatol. 2025年9卷1期56页
The identification of responders to methotrexate (MTX) would optimize the therapy of patients with early rheumatoid arthritis (eRA). Our aim was to identify protein biomarkers for the prediction of the response to MTX.
354. The impact of intensive management on pain intensity in patients with rheumatoid arthritis and psoriatic arthritis: secondary analysis of three clinical trials.
Understanding the impact of intensive treatment on pain in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is crucial to informing the application of evidence-based arthritis pain care. The impact of intensive treatment on inflammatory arthritis pain has received relatively limited attention. We addressed this through a detailed secondary analysis of three trials evaluating varying intensities of disease-modifying anti-rheumatic drug treatment. We considered a range of pain outcomes of clinical relevance to patients, including the achievement of mild endpoint pain scores and clinically-meaningful pain reductions.
355. NETs in the spotlight: exploring NETosis markers for tracking disease activity in IgA vasculitis.
作者: Vafa Guliyeva.;Fatma Gül Demirkan.;Erdem Bektaş.;Rabia Deniz.;Zeliha Emrence.;Özlem Akgün.;Selen Duygu Arık.;Ayşenur Doğru.;Ayşe Tanatar.;Neslihan Abacı.;Sema Sırma Ekmekci.;Ahmet Gül.;Nuray Aktay Ayaz.
来源: Rheumatology (Oxford). 2025年64卷10期5509-5517页
The role of neutrophil extracellular traps (NETs) in IgA vasculitis (IgAV) pathogenesis is emerging, with NETosis-associated markers potentially linked to disease activity. This study aimed to explore the relationship between NETosis biomarkers and IgAV disease phases.
357. Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study.
作者: Anna-Maria Hoffmann-Vold.;Liubov Petelytska.;Håvard Fretheim.;Trond Mogens Aaløkken.;Mike Oliver Becker.;Hilde Jenssen Bjørkekjær.;Cathrine Brunborg.;Cosimo Bruni.;Christian Clarenbach.;Phuong Phuong Diep.;Rucsandra Dobrota.;Michael T Durheim.;Muriel Elhai.;Thomas Frauenfelder.;Suiyuan Huang.;Suzana Jordan.;Emily Langballe.;Øyvind Midtvedt.;Carina Mihai.;Erica Mulcaire-Jones.;Janelle Vu Pugashetti.;Marco Sprecher.;Justin Oldham.;Øyvind Molberg.;Dinesh Khanna.;Oliver Distler.
来源: Lancet Rheumatol. 2025年7卷7期e463-e471页
In patients with systemic sclerosis, it is common practice to treat interstitial lung disease (ILD) in patients in whom progression has already occurred. We sought to clarify whether observed progression of systemic sclerosis-associated ILD confers risk for subsequent progression.
358. Performance of the Large Language Models in African rheumatology: a diagnostic test accuracy study of ChatGPT-4, Gemini, Copilot, and Claude artificial intelligence.
作者: Yannick Laurent Tchenadoyo Bayala.;Wendlassida Joelle Stéphanie Zabsonré/Tiendrebeogo.;Dieu-Donné Ouedraogo.;Fulgence Kaboré.;Charles Sougué.;Aristide Relwendé Yameogo.;Wendlassida Martin Nacanabo.;Ismael Ayouba Tinni.;Aboubakar Ouedraogo.;Yamyellé Enselme Zongo.
来源: BMC Rheumatol. 2025年9卷1期54页
Artificial intelligence (AI) tools, particularly Large Language Models (LLMs), are revolutionizing medical practice, including rheumatology. However, their diagnostic capabilities remain underexplored in the African context. To assess the diagnostic accuracy of ChatGPT-4, Gemini, Copilot, and Claude AI in rheumatology within an African population.
359. Effect of rituximab on long-term damage acquisition in patients with systemic lupus erythematosus.
作者: Amanda da Silva Brito.;Sofia Miranda.;Teresa Moitinho de Almeida.;David A Isenberg.
来源: Rheumatology (Oxford). 2025年64卷9期5031-5036页
B-cell depletion therapy has been used for over two decades to treat SLE, but there is a lack of studies reporting its impact on damage progression. This study aims to assess the effectiveness of rituximab in slowing damage acquisition.
360. Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacy.
作者: Saskia R Veldkamp.;Maud Reugebrink.;Sanne W Evers.;Thomas R J Moreau.;Vincent Bondet.;Wineke Armbrust.;J Merlijn van den Berg.;Petra C E Hissink Muller.;Sylvia Kamphuis.;Ellen Schatorjé.;Eveline M Delemarre.;Anneke J van der Kooi.;Brigitte Bader-Meunier.;Darragh Duffy.;Mathieu P Rodero.;Joost Raaphorst.;Annet van Royen-Kerkhof.;Marc H A Jansen.;Femke van Wijk.
来源: Rheumatology (Oxford). 2025年64卷9期5132-5141页
For IFN-driven diseases, such as juvenile dermatomyositis (JDM), there is a critical need for targeted therapies. We aimed to develop an in vitro model, using Siglec-1 as read-out, to evaluate inhibition of IFN-mediated responses with different JAK inhibitors (JAKi).
|